Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease

被引:50
作者
Ecder, T
Edelstein, CL
Chapman, AB
Johnson, AM
Tison, L
Gill, EA
Brosnahan, GM
Schrier, RW
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Med, Sch Med,Div Renal Dis & Hypertens, Denver, CO 80262 USA
[2] Univ Colorado, Sch Med, Div Cardiol, Dept Med, Denver, CO 80262 USA
[3] Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA
关键词
ACE inhibitors; left ventricular hypertrophy; polycystic kidney disease;
D O I
10.1093/ndt/14.5.1113
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Hypertension occurs commonly and early in the natural history of autosomal dominant polycystic kidney disease (ADPKD), affecting both renal and patient outcome. Activation of the renin-angiotensin-aldosterone system due to cyst expansion and local renal ischaemia plays an important role in the development of ADPKD related hypertension and left ventricular hypertrophy (LVH), a known important risk factor for cardiovascular morbidity and mortality. The aim of this study was to investigate the effects of an angiotensin converting enzyme (ACE) inhibitor, enalapril, on renal function, blood pressure and LVH in hypertensive ADPKD patients. Methods. Fourteen hypertensive ADPKD patients (II men, 3 women; mean age: 40 years) were included in the study. All patients had LVH and creatinine clearance (Cer) greater than 50ml/min/1.73m(2). The patients were followed for 7 years on enalapril therapy. The effects of enalapril on renal function, blood pressure and LVH were investigated. Results. Baseline measurements of mean arterial pressure (MAP), Ccr and left ventricular mass index (LVMI) were 110+/-2mmHg, 84+/-6ml/min/1.73m(2) and 146 +/- 4 g/m(2), respectively. After one year of enalapril therapy there was a significant decrease in MAP (94 +/- 3 mmHg, P< 0.005) which remained stable until the end of the study at 7 years (94 +/- 1 mmHg, P < 0.005 vs baseline). There was also a significant decrease in LVMI (131+/-6 g/m(2), P< 0.05) after year I which continued to decrease until the end of the study reaching 98 +/- 6 g/m(2) (P < 0.01 vs year 1 and baseline). Although Ccr remained stable after year I, a significant decrease was observed after 7 years of follow-up (59 +/- 6 ml/min, P<0.001 vs year 1 and baseline). Conclusions. ACE inhibition in hypertensive ADPKD patients provided long-term reversal of LVH in association with a mean 3.6 ml/min/year decline of Ccr. These preliminary results have potential important implications for cardiovascular and renal protection in ADPKD.
引用
收藏
页码:1113 / 1116
页数:4
相关论文
共 23 条
[11]   RENAL STRUCTURE AND HYPERTENSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
GABOW, PA ;
CHAPMAN, AB ;
JOHNSON, AM ;
TANGEL, DJ ;
DULEY, IT ;
KAEHNY, WD ;
MANCOJOHNSON, M ;
SCHRIER, RW .
KIDNEY INTERNATIONAL, 1990, 38 (06) :1177-1180
[12]   AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
GABOW, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :332-342
[13]   FACTORS AFFECTING THE PROGRESSION OF RENAL-DISEASE IN AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
GABOW, PA ;
JOHNSON, AM ;
KAEHNY, WD ;
KIMBERLING, WJ ;
LEZOTTE, DC ;
DULEY, IT ;
JONES, RH .
KIDNEY INTERNATIONAL, 1992, 41 (05) :1311-1319
[14]   THE ANATOMY OF THE RENIN-SECRETING CELL IN ADULT POLYCYSTIC KIDNEY-DISEASE [J].
GRAHAM, PC ;
LINDOP, GBM .
KIDNEY INTERNATIONAL, 1988, 33 (06) :1084-1090
[15]  
KLAHR S, 1988, NEW ENGL J MED, V318, P1657
[16]   THE EFFECTS OF DIETARY-PROTEIN RESTRICTION AND BLOOD-PRESSURE CONTROL ON THE PROGRESSION OF CHRONIC RENAL-DISEASE [J].
KLAHR, S ;
LEVEY, AS ;
BECK, GJ ;
CAGGIULA, AW ;
HUNSICKER, L ;
KUSEK, JW ;
STRIKER, G ;
BUCKALEW, V ;
BURKART, J ;
FURBERG, C ;
FELTS, J ;
MOORE, M ;
ROCCO, H ;
DOLECEK, T ;
WARREN, S ;
BEARDEN, B ;
STARKEY, C ;
HARVEY, J ;
POOLE, D ;
DAHLQUIST, S ;
DOROSHENKO, L ;
BRADHAM, K ;
WEST, D ;
AGOSTINO, J ;
COLE, L ;
BAKER, B ;
HAIRSTON, K ;
BURGOYNE, S ;
LAZARUS, J ;
STEINMAN, T ;
SEIFTER, J ;
DESMOND, M ;
FIORENZO, M ;
CHIAVACCI, A ;
METALIDES, T ;
KORZECRAMIREZ, D ;
GOULD, S ;
PICKETT, V ;
PORUSH, J ;
FAUBERT, P ;
SPITALEWITZ, S ;
FAUBERT, J ;
ZIMMER, G ;
SAUM, D ;
BLOCK, M ;
WOEL, J ;
ROSE, M ;
DENNIS, V ;
SCHWAB, S ;
MINDA, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (13) :877-884
[17]   RELATION OF LEFT-VENTRICULAR MASS AND GEOMETRY TO MORBIDITY AND MORTALITY IN UNCOMPLICATED ESSENTIAL-HYPERTENSION [J].
KOREN, MJ ;
DEVEREUX, RB ;
CASALE, PN ;
SAVAGE, DD ;
LARAGH, JH .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (05) :345-352
[18]   REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY FROM SYSTEMIC HYPERTENSION BY ENALAPRIL [J].
NAKASHIMA, Y ;
FOUAD, FM ;
TARAZI, RC .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (08) :1044-1049
[19]   ANGIOTENSIN II - RAPID LOCALIZATION IN NUCLEI OF SMOOTH AND CARDIAC MUSCLE [J].
ROBERTSON, AL ;
KHIARALL.PA .
SCIENCE, 1971, 172 (3988) :1138-+
[20]   RECOMMENDATIONS REGARDING QUANTITATION IN M-MODE ECHOCARDIOGRAPHY - RESULTS OF A SURVEY OF ECHOCARDIOGRAPHIC MEASUREMENTS [J].
SAHN, DJ ;
DEMARIA, A ;
KISSLO, J ;
WEYMAN, A .
CIRCULATION, 1978, 58 (06) :1072-1083